Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 4
---
) 
     -  
     -  
     (127,144) 
     -  
     -  
     (395,000)
  
     Share-based inducement
    expense related to conversion of Series A Preferred Stock 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     156,250  
     -  
     -  
     156,250 
  
    Stock-based
    compensation 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     304,946  
     -  
     -  
     304,946 
  
    Net
    loss 
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     -  
     (5,105,931) 
     (5,105,931)
  
    Balance
    at March 31, 2025 (Successor) 
     1,429  
    $1,287,315  
     198  
    $158,147  
     2,537  
    $982,143  
     5,169,723  
    $517  
    $73,345,026  
    $(78,750) 
    $(76,023,784) 
    $(329,386)

    Convertible Preferred Stock  
    Series A Common  
    Additional  
    Stock  
       
    Total 

    Series A  
    Series B  
    Series C  
    Stock  
    Paid-in  
    Subscriptions  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Deficit 

    Balance at February 14, 2024 (Successor) 
     10,089